Shanghai Changzheng Hospital: Multiple Myeloma trials

The registry lists 11 Multiple Myeloma studies with Shanghai Changzheng Hospital as lead sponsor. 3 are open to participants now and 1 have results posted.

Early Phase 1 6Phase 1 3Phase 2 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRecruitingNCT06718270Early Phase 1
• Study of CT071 Injection in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT06407947Early Phase 1
• Study of FasT CAR-T GC012F Injection NDMM PatientsRecruitingNCT05840107Early Phase 1
• A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple MyelomaCompletedNCT01852799Phase 2Results posted
• Study of CT071 Injection in RRMM or PPCLActive, not recruitingNCT05838131Early Phase 1
• Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple MyelomaStatus unknownNCT05412329Phase 1
• BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT05376345Phase 1
• Study of FasT CAR-T GC012F Injection in High Risk TE NDMM PatientsStatus unknownNCT04935580Phase 1/2
• BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple MyelomaStatus unknownNCT04617704Early Phase 1
• BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple MyelomaStatus unknownNCT04236011Early Phase 1
• Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple MyelomaStatus unknownNCT04122092